



(51) International Patent Classification:

C07D 403/12 (2006.01) C07D 409/14 (2006.01)
 C07D 401/14 (2006.01) C07D 417/12 (2006.01)
 C07D 401/12 (2006.01) C07D 417/14 (2006.01)
 C07D 403/14 (2006.01) A61P 35/00 (2006.01)
 C07D 407/14 (2006.01)

(21) International Application Number:

PCT/IB2013/054145

(22) International Filing Date:

20 May 2013 (20.05.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/649,645 21 May 2012 (21.05.2012) US
 61/695,533 31 August 2012 (31.08.2012) US

(71) Applicant (for all designated States except US): NOVARTIS AG [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(72) Inventors; and

(71) Applicants (for US only): BURGER, Matthew [US/US]; Novartis Vaccines and Diagnostics, Inc., 4560 Horton Street, Emeryville, California 94608-2916 (US). DRUMM III, Joseph [US/US]; Novartis Vaccines and Diagnostics, Inc., 4560 Horton Street, Emeryville, California 94608-2916 USA (US). NISHIGUCHI, Gisele [US/US]; Novartis Vaccines and Diagnostics, Inc., 4560 Horton Street, Emeryville, California 94608-2916 (US). RICO, Alice [US/US]; Novartis Vaccines and Diagnostics, Inc., 4560 Horton Street, Emeryville, California 94608-2916 (US).

SIMMONS, Robert Lowell [US/US]; Novartis Vaccines and Diagnostics, Inc., 4560 Horton Street, Emeryville, California 94608-2916 (US). TAFT, Benjamin [US/US]; Novartis Vaccines and Diagnostics, Inc., 4560 Horton Street, Emeryville, California 94608-2916 (US). TANNER, Huw [GB/US]; Novartis Vaccines and Diagnostics, Inc., 4560 Horton Street, Emeryville, California 94608-2916 (US).


(74) Common Representative: NOVARTIS AG; Lichtstrasse 35, CH-4056 Basel (CH).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: NOVEL RING-SUBSTITUTED N-PYRIDINYL AMIDES AS KINASE INHIBITORS



(57) Abstract: The present invention provides a compound of formula (A): I as described herein, and pharmaceutically acceptable salts, enantiomers, rotamers, tautomers, or racemates thereof. Also provided are methods of treating a disease or condition mediated by PIM kinase using the compounds of Formula I, and pharmaceutical compositions comprising such compounds.



Published:

— *with international search report (Art. 21(3))*